Project Grant R43HG013444

Award Date 2/15/24
Completion Date 2/14/26
Dollars Obligated $717K
Federal Grant Program
93.172
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), provides $700,000 to Mirimus, Inc. to support the creation of next-generation RNA interference (RNAi) therapeutics and an in vivo model for evaluating their efficacy and biodistribution. The key products and services to be delivered include: 1) Developing optimized siRNAs and artificial miRNA scaffolds for RNAi-based therapeutics; 2)...
This $350,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) aims to develop the first technology capable of high-accuracy sequencing of the RNA modifications pseudouridine (Ψ) and N6-methyladenosine (m6A). This collaborative effort between academia and industry will merge innovative bisulfite adduct methodology with an enzyme-free, multipass nanopore nucleic acid characterization...
This Project Grant award, valued at $215,088.00 and funded by the National Institutes of Health's National Human Genome Research Institute (CFDA 93.172 - Human Genome Research), supports the development of an "Exhaustive De Novo Sequencing of Every RNA in a Sample by a Layer-by-Layer Mass Spectrometry Ladder Intensity Approach" at Directseq Biosciences, Inc. The project aims to 1) further develop a next-generation mass spectrometry-based RNA sequencing method that can comprehensively...
This $406,500 Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research Federal Grant Program (CFDA 93.172), aims to advance next-generation mass spectrometry-based sequencing (NGMS-SEQ) methods for comprehensive, unbiased sequencing and quantitative mapping of RNA modifications. The key objectives are to: 1) Increase the throughput of NGMS-SEQ to directly sequence various physiologically relevant tRNA samples, and 2) Enhance the...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) is funding research to develop an enzyme-free, label-free quantitative microarray technology capable of detecting and quantifying small nucleic acid sequences, such as microRNA, at attomolar concentrations. The $432,834 award to the University of Nebraska aims to design a novel "binary probe" system and specialized opto-electrochemical...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The goal of this 1-year project is to develop a novel nanopore-based sequencing approach that can accurately characterize repetitive DNA sequences, which are critical for understanding cancer progression but challenging to analyze using current sequencing...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $2,078,214 to Precision Epigenomics Inc., a University of Arizona spin-out company, to conduct a multi-site clinical validation study for their "Sentinel-MPE" liquid biopsy test. The goal is to establish the Sentinel-MPE test as a new commercial molecular diagnostic tool for the identification of malignant pleural effusions (MPEs), which...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
This Project Grant award of $680,453 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to develop and validate a liquid biopsy approach using circulating tumor DNA (ctDNA) fragmentomics as prognostic and treatment resistance biomarkers for metastatic castration-resistant prostate cancer (mCRPC). The research aims to: 1) determine if baseline ctDNA fragmentomics scores are prognostic biomarkers for mCRPC, 2) detect...
The National Cancer Institute (NCI) awarded the Icahn School of Medicine at Mount Sinai a $237,023 Project Grant under the Cancer Biology Research (CFDA 93.396) program to develop a scalable and cost-effective single-cell multi-omic profiling method (SHARE-ME-SEQ). This method will jointly capture gene expression, chromatin accessibility, and DNA methylation at the single-cell level, with the goal of identifying and targeting methylation-driven pathways in acute myeloid leukemia (AML). The...

A RAPID METHOD FOR GLOBAL AND TARGETED MIRNA NEXT GENERATION SEQUENCING - PROJECT SUMMARY MICRORNAS (MIRNAS) ARE SMALL NON-CODING RNAS (15-25 NT) THAT PLAY A PIVOTAL ROLE IN THE REGULATION OF PROTEIN SYNTHESIS BY MODULATING MRNA TRANSLATION. MIRNA EXPRESSION, LOCALIZATION AND SECRETION ARE CLOSELY MODULATED IN RESPONSE TO BIOLOGICAL STIMULI. THESE PROCESSES ARE OFTEN DYSREGULATED IN CANCER RESULTING IN MIRNA EXPRESSION PROFILES THAT ARE UNIQUE TO CANCER TYPE AND STAGE. APART FROM ITS UTILITY IN EARLY CANCER DETECTION, TUMOR MIRNA PROFILING HAS BEEN SHOWN TO IMPROVE PATIENT SURVIVAL WHEN USED IN TREATMENT RESPONSE MONITORING. RECENT LIQUID BIOPSY STUDIES HAVE DEMONSTRATED THE UTILITY OF MIRNAS AS CIRCULATING BIOMARKERS FOR EARLY CANCER DIAGNOSIS AND FOR MONITORING DISEASE PROGRESSION AND TREATMENT RESPONSE. HOWEVER, EXISTING ASSAYS ARE NOT SENSITIVE TO THE SUBTLE CHANGES IN MIRNA PROFILES AND REQUIRE PRIOR KNOWLEDGE OF THE DYSFUNCTIONAL MIRNAS. WHILE NEXT-GENERATION SEQUENCING (NGS) CAN BE USED FOR AGNOSTIC MIRNA PROFILING, THERE IS A CLEAR LACK OF A RAPID, EASILY ADMINISTRABLE NGS-BASED MOLECULAR DIAGNOSTIC ASSAY THAT EFFICIENTLY CAPTURES SUBTLE CHANGES IN MICRORNA PROFILES DURING DISEASE PROGRESSION OWING TO THE SMALL SIZE AND SCARCITY OF MIRNA IN BIOLOGICAL SAMPLES, PARTICULARLY IN BIOLOGICAL FLUIDS. IN THIS APPLICATION WE PROPOSE TO DEVELOP A NOVEL APPROACH CALLED MIREALLY THAT DIRECTLY CONVERTS MIRNA TO SEQUENCE-READY LIBRARIES IN JUST TWO STEPS - DIRECT LIGATION OF CLARETBIO'S PROPRIETARY ADAPTERS TO MIRNA, FOLLOWED BY A STEP THAT PERFORMS REVERSE- TRANSCRIPTION AND LIBRARY-AMPLIFICATION IN A SINGLE REACTION. THE PROOF OF CONCEPT WORK DESCRIBED HERE WILL IDENTIFY THE IDEAL COMBINATION OF REAGENTS AND ENZYMES THAT FACILITATE EFFICIENT LIBRARY CONVERSION, WITH METRICS THAT OUTPERFORM CURRENT SMALL-RNASEQ METHODOLOGIES. IN AIM 2 WE WILL FURTHER OPTIMIZE THE PROTOCOL AND DETERMINE THE LIMIT OF DETECTION AND INPUT RANGE TO EXPAND THE UTILITY OF THE APPROACH WITH BIOLOGICAL SAMPLES USING NON- SMALL CELL LUNG CANCER AS A MODEL. FINALLY IN AIM 3 WE WILL LEVERAGE THE UNIQUE DESIGN OF THE ADAPTERS FOR TARGETED ENRICHMENT OF MIRNA - BY DESIGNING SPLINT ADAPTERS WITH SEQUENCE COMPLEMENTARITY TO THE ENDS OF A SPECIFIC MIRNA FROM COMPLEX MIRNA MIXTURES. THIS ALLOWS CAPTURE OF A PANEL OF KNOWN MIRNA AND THEIR VARIANTS IN A SINGLE WORKFLOW, ELIMINATING THE NEED FOR ADDITIONAL TARGETED ENRICHMENT STEPS. ACCOMPLISHING THE AIMS DESCRIBED HERE WOULD RESULT IN A ROBUST MIRNA NGS ASSAY THAT NOT ONLY ENABLES GLOBAL MIRNA PROFILING BUT ALSO HELPS MONITOR CHANGES TO LEVELS OF SPECIFIC MIRNA BIOMARKERS AND THEIR VARIANTS THEREBY IMPROVING OUR UNDERSTANDING OF INTRACELLULAR AND CIRCULATING MIRNA BIOLOGY AND FACILITATING MORE PRECISE DISEASE DIAGNOSIS AND MONITORING IN THE CLINICAL SETTING.

Posted 2/15/24, 12:00 AM